This statement applies to all parties involved in the publishing process of Jurnal Buana Farma—the publisher, editors, peer reviewers, and authors. The policy follows the COPE (Committee on Publication Ethics) guidelines, the BRIN (Arjuna/SINTA) guidance for research and publication ethics, and the DOAJ Principles of Transparency and Best Practice in Scholarly Publishing.

Core values: Neutrality (freedom from conflicts of interest), Fairness (appropriate authorship), and Honesty (free from duplication, fabrication, falsification, and plagiarism/DF2P).

1. Duties and Responsibilities of the Publisher

• Define the journal’s title, scope, periodicity, and accreditation where applicable.
• Appoint the editorial board and establish clear relationships among publisher–editor–reviewer through guidelines/contracts.
• Safeguard confidentiality of authors, editors, and reviewers; comply with IP/copyright law.
• Periodically review and disseminate journal policies; provide ethical guidelines for editors and reviewers.
• Ensure continuity of publication (funding, infrastructure, digital preservation/archiving).
• Build collaborations and ensure all legal requirements for publishing are fulfilled.

2. Duties and Responsibilities of Editors

• Conduct fair and objective desk evaluation according to focus–scope and author guidelines.
• Ensure a high-quality, transparent peer review process; maintain academic record integrity.
• Manage conflicts of interest and maintain confidentiality of submitted manuscripts.
• Issue corrections, clarifications, retractions, or expressions of concern when necessary in line with COPE.
• Promote adherence to research ethics (ethical clearance and informed consent where relevant).
• Remain open to new scholarly views and avoid biased decisions.

3. Duties and Responsibilities of Reviewers

• Provide objective, constructive, and timely evaluations in accordance with scientific standards.
• Decline to review when conflicts of interest or personal involvement with authors/affiliations exist.
• Maintain confidentiality; never use privileged information for personal advantage.
• Offer clear feedback on methodology, originality, analysis, conclusions, and ethical compliance.

4. Duties and Responsibilities of Authors

• Ensure authorship is limited to those who made significant contributions; all authors approve the final version.
• Take collective responsibility for content (methods, analysis, data, and findings).
• Disclose all sources of funding and potential conflicts of interest.
• Confirm originality: the manuscript has not been published and is not under consideration elsewhere.
• Respond to reviewers’ comments professionally and in a timely manner; state study limitations honestly.
• Provide ethical approval details/IRB number and informed consent statements when involving humans/animals.

5. Additional Policies

5.1 Data Access and Retention

Authors may be requested to provide raw data for editorial verification and are expected to retain such data for a reasonable period after publication. Where feasible, data should be made publicly available in reputable repositories with proper citation.

5.2 Originality and Plagiarism

Manuscripts must be original. All quotations and paraphrases from other works must be properly attributed. Jurnal Buana Farma screens submissions with similarity-checking software (e.g., Turnitin) and enforces the journal’s Plagiarism Policy.

5.3 Multiple, Redundant, or Concurrent Publication

Submitting the same or substantially similar manuscripts to more than one journal concurrently is unethical and unacceptable. Secondary publication (e.g., clinical guidelines or translations) may be justified only with prior editor consent and full citation of the primary publication.

5.4 Acknowledgement of Sources

Proper acknowledgement of others’ work is mandatory. Privately obtained information (e.g., conversations, correspondence, peer review) must not be used without explicit written permission from the source.

5.5 Authorship

Authorship is restricted to those with significant contributions (conception, design, execution, or interpretation). Other substantial contributors should be acknowledged. The corresponding author ensures that all co-authors approve the final manuscript prior to submission.

5.6 Hazards and Human/Animal Subjects

If the study involves hazardous chemicals, procedures, or equipment, this must be clearly identified in the manuscript. For human or animal studies, authors must confirm compliance with relevant laws and institutional guidelines, approval by the ethics committee/IRB, and (for human participants) informed consent.

5.7 Ethical Approval

Research articles must include the name of the ethics committee/IRB, the approval number/ID, and a statement that informed consent was obtained from participants (where applicable).

5.8 Disclosure and Conflicts of Interest

Authors must disclose all financial and non-financial conflicts of interest that could influence the results or interpretation of the manuscript, and must declare all sources of funding and research support.

6. Handling Ethical Misconduct

Allegations of ethical misconduct will be handled in accordance with the COPE Flowcharts, including correction, clarification, retraction, or expression of concern where appropriate. Final decisions rest with the Editor-in-Chief based on evidence and recommendations from the editorial board/reviewers.

By enforcing this policy, Jurnal Buana Farma is committed to maintaining integrity, transparency, and accountability throughout the scholarly publishing process.